Book a meeting
DO-BO

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

Dive deep into the heart of French market access with Dr. Stefan Walzer and Dr. Benoit Salaun on this episode of the Map Podcast. As experts in their fields, they dissect the intricacies of the French healthcare system, focusing on medical device reimbursement, and revealing the critical steps to success in this competitive landscape.

This episode is a goldmine for healthcare professionals, medtech innovators, and market access strategists seeking to penetrate the French market effectively. Gain unparalleled insights into securing the optimal position and price for your medical device in France. Embark on your journey to mastering French market access with expert guidance—listen today!

Related

Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

By

Stefan Walzer

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe […]

From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?

By

Stefan Walzer

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?

By

Stefan Walzer

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]